Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Xenon Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the biopharmaceutical company will post earnings of ($2.41) per share for the year. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.13) per share.
XENE has been the subject of several other reports. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Raymond James reaffirmed an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright restated a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $56.00.
Get Our Latest Stock Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Trading Up 2.0 %
XENE traded up $0.79 on Thursday, reaching $39.98. The company had a trading volume of 341,746 shares, compared to its average volume of 390,195. The company has a market capitalization of $3.05 billion, a P/E ratio of -14.18 and a beta of 1.20. The company has a fifty day moving average of $40.23 and a 200-day moving average of $40.79. Xenon Pharmaceuticals has a one year low of $35.53 and a one year high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the firm posted ($0.73) earnings per share.
Insider Buying and Selling at Xenon Pharmaceuticals
In related news, CFO Sherry Aulin sold 18,709 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary Patou sold 4,891 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. This trade represents a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.52% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. Blue Trust Inc. lifted its position in shares of Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 641 shares in the last quarter. Avior Wealth Management LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at approximately $101,000. nVerses Capital LLC purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter worth approximately $102,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after buying an additional 487 shares during the period. Finally, KBC Group NV grew its holdings in shares of Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 780 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
